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Allopurinol is a xanthine oxidase inhibitor mainly used
to reduce circulating urate (also known as uric acid)
levels. This helps to prevent recurrent urate crystal
deposition in the form of gout.1 Gout is relatively
common in patients with renal failure. Although rou-
tine dose reduction of allopurinol is recommended in
the hemodialysis (HD) population this is not based
on evidence from robust clinical trials.2 Guidelines
generally recommend aiming to reduce urate levels by
50% to protect against future gout episodes.3 This study
aimed to determine the optimal dose of allopurinol to
achieve this in the HD population.
Determining an optimal dose of allopurinol to use
in the HD population will first help to guide clinicians
in their treatment of their HD patients who develop
gout. Second, patients with end-stage renal disease are
at greatly increased risk of cardiovascular disease and
death.4 Urate levels are known to be higher in the
chronic kidney disease (CKD) population than in the
general population.5 We know from large observational
studies that increased urate levels are strongly associ-
ated with an increased cardiovascular risk, in both the
general and CKD populations.6–9
In addition to its urate-lowering abilities, allop-
urinol itself has some specific properties that make
it a potentially attractive drug to use in the HD
population. Allopurinol has been shown to improve
endothelial function in several population groups—
including CKD patients—who are prone to endothe-
lial dysfunction.10–12 In a large observational study
the use of allopurinol was associated with reduced
cardiovascular and all-cause mortality in patients un-
dergoing HD who had no history of cardiovascular
disease.13 In addition to this, allopurinol has also been
demonstrated to regress left ventricular hypertrophy
(LVH) in CKD, diabetic patients and in those with
ischemic heart disease.10,11,14 Given that reduction in
left ventricular mass is a common therapeutic target in
the HD population,15–18 it is a natural question whether
allopurinol might also regress LVH in this population.
Until now this had not been investigated in a robust
prospective clinical trial.
We therefore designed a clinical trial to investigate
this, the ALTERED (Does ALlopurinol regress lefT
ventricular hypertrophy in End stage REnal Disease)
study. This study looked to address this question
through a multicenter randomized, placebo-controlled,
double-blind trial of allopurinol. The primary outcome
of the ALTERED study is change in left ventricular
mass measured by cardiac magnetic resonance imaging
at follow-up from baseline after 1 year of therapy.
For the reasons described above, defining the optimal
dose of allopurinol to use in this study was a priority.
The first stage of the ALTERED study was therefore
an open-label dose-escalation study to determine the
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optimum dose of allopurinol to use in the prospective
blinded study. The results of this dose-finding study are
presented in this article.
Methods
This study was approved by the Medicines and Health-
care Products Regulatory Agency (United Kingdom;
EudraCT number 2013-001436-22) and by the East
of Scotland Ethics Committee (13/ES/0051). All par-
ticipants gave full written and informed consent. The
study was registered online with clinicaltrials.gov (trial
number: NCT01951404). Protocol version 1.1, dated
April 11, 2013, was in use during this dose-finding study
(see Supplementary Information for full protocol).
The primary outcome of this dose-finding study was
to determine which dose of active allopurinol reduced
serum urate by 41% in theHDpopulation. A secondary
outcome of this study, in addition to the main study,
was to help to determine the safety and tolerability of
allopurinol in this population group.
Patients were eligible for this open-label dose-finding
study if they were aged 18 to 80 years, had end-stage
renal disease (CKD stage 5), and had been on HD for
at least 3 months.
Patients for the dose-finding study were recruited as
representative of those to be studied in the larger HD
clinical trial. Exclusion criteria were: known heart fail-
ure or left ventricular ejection fraction < 45%; already
had gout or taking allopurinol; severe hepatic disease;
on azathioprine, 6-mercaptopurine, theophylline, or
warfarin; malignancy or other life-threatening diseases;
pregnant or lactating women; any contraindication to
magnetic resonance imaging; with a planned (relative)
kidney transplant; younger than 18 years or older
than 80 years; above-ankle amputees; patients who
had participated in any other clinical trial within the
previous 30 days; patients who were unable to give
informed consent; and any other reason considered by
a study physician to make someone inappropriate for
study inclusion.
The study protocol specified that 10 patients would
have a screening visit at which serum urate would be
checked. Blood was sampled from the venous port of
the HD circuit prior to commencement of the HD
session. Thereafter, patients would receive open-label
100 mg of allopurinol after each dialysis session for
3 sessions. Serum urate was then checked at the com-
mencement of the fourth dialysis session. Thereafter,
the allopurinol dose was increased to 200 mg and the
same procedure repeated. The next step was 250mg and
then 300 and 350 mg (maximum dose). In keeping with
published recommendations to ensure safe prescribing
of allopurinol in end-stage renal disease,19 the dose
escalation was planned to stop in each patient, when
Table 1. Baseline Patient Characteristics
Patient Parametera Value
Male (%) 90
Age (years) 53 ± 9.4
White (%) 100
Body mass index (kg/m2) 25.0 (IQR 21.8–26.9)
Diabetes (%) 30
Hypertension (%) 80
Ischemic heart disease (%) 10
Dialysis mode: post-HDF (%) 80
Hemodialysis (%) 20
Urea reduction ratio (%) 72 ± 7.0
Ultrafiltration volume (L) 1.5 ± 1.2
Predialysis systolic BP (mm Hg) 152 ± 22.0
Predialysis diastolic BP (mm Hg) 69.8 ± 17.9
For baseline patient characteristics,mean ± standard deviation are presented
for normally distributed data and median (interquartile range) is presented for
nonnormally distributed data or percentage of whole cohort where relevant.
BP, blood pressure; HDF, hemodiafiltration; IQR, interquartile range.
aParameters given are values at baseline visit.
serum urate had fallen by 50% from the screening visit
urate in that patient.
Safety blood tests, vital signs, adverse events, and
medication records were reviewed at each study visit.
Using the collected pilot data, we planned to calculate
which of the above doses of allopurinol (given at the
end of each dialysis session) produced on average a 41%
fall in serum urate. We planned to use this dose for the
prospective blinded trial.
All patients received their usual dialysis care
throughout their participation in the study. Dialysis
modalities are shown in Table 1.
Statistical Methods
All data were analyzed using SPSS version 22. Con-
tinuous data are presented as mean ± standard devi-
ation if parametric or median (interquartile range) if
nonnormally distributed; categorical data are presented
as a percentage. After testing for normal distribu-
tion, a repeated-measures analysis of variance with
a Greenhouse-Geisser correction was used to deter-
mine any statistically significant difference in urate
at each dose of allopurinol. A Bonferroni correction
was used to adjust for within-subject baseline urate
in our analysis. Correlations between continuous in-
dices were assessed using Pearson and Spearman cor-
relation coefficients for parametric and nonparametric
data, respectively. P < .05 was considered statistically
significant.
Results
Eleven patients, all of whom were receiving regular
HD at Ninewells Hospital, Dundee, Scotland, UK,
consented to participate in the study. All patients
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Table 2. Mean Serum Urate Values at Each Dose of Allopurinol
Visit Mean Urate ± Standard Deviation (mg/dL) Pa
Baseline 6.3 ± 1.1 N/A
After 100 mg 5.9 ± 0.9 1.0
After 200 mg 5.6 ± 0.7 1.0
After 250 mg 5.5 ± 1.1 1.0
After 300 mg 4.9 ± 1.0 0.04
After 350 mg 5.2 ± 1.0 0.5
aAdjusted for baseline urate using a Bonferroni correction.
Figure 1. Plot of individual urates at each dose of allopurinol.
commenced the study during October 2013. On screen-
ing, 1 participant was ineligible; therefore, 10 par-
ticipants, 9 men and 1 woman, proceeded into the
open-label study. Full participant demographics and
baseline parameters of the included participants are
shown in Table 1.
The mean urate on study commencement was 6.3 ±
1.1 mg/dL (normal laboratory reference range: males,
3.4–7.2 mg/dL; females, 2.4–6.1 mg/dL). Baseline urate
was negatively correlated with age (r= -0.766; P= .01).
There was no correlation of baseline urate with blood
pressure, ultrafiltration volume, urea reduction ratio, or
body mass index.
No patient reached a urate reduction of 50% on any
dose of allopurinol. The greatest individual percentage
reduction in urate by any patient was 45.4%, in a
single patient while taking allopurinol 350 mg. This
was achieved in the patient with the highest starting
urate (baseline urate, 8.3 mg/dL), the only patient with
a baseline urate outside the normal range.
Overall, only allopurinol 300 mg achieved a statis-
tically significant reduction in predialysis serum urate
from baseline (mean urate at baseline, 6.3 ± 1.1 mg/dL;
visit 6 [allopurinol 300 mg], 4.9 ± 1.0 mg/dL; P =
.04; Table 2). Figure 1 shows a plot of urates for each
patient at each dose of allopurinol. The greatest mean
reduction in urate was achieved with the 300-mg dose
of allopurinol (see Figure 2).
Figure 2. Box plot of reduction in urate from baseline with each dose of
allopurinol, with 95% confidence intervals. A significant mean reduction
in urate was seen with the 300-mg dose of allopurinol. *P < .05.
There were 22 adverse events during the course of
the study. All were minor in nature and typical of
normal events seen in dialysis patients. Two episodes
of nausea and a single episode of loose stool were the
only events that could possibly have been attributed
to allopurinol—these 3 episodes were all self-limiting.
There were no reported skin rashes. There were no
statistically significant changes in white cell count,
hemoglobin, liver function tests, phosphate, or potas-
sium from the baseline visit to the end of the study
(Table 3). The cumulative dose of allopurinol and
number of doses of allopurinol that each patient had
been exposed to at each visit are also shown in Table 3.
Discussion
Study Rationale
Since its discovery more than 50 years ago, allopuri-
nol has been the mainstay therapy for prevention of
recurrent gout.1 It is also indicated for the prophylaxis
of hyperuricemia associated with malignancy or with
the treatment of malignancy.20 Allopurinol is further
utilized in the management of renal stone disease (both
calcium oxalate stones and uric acid stones).20
More recently there has been emerging interest in the
potential utility of allopurinol to reduce cardiovascular
disease risk.21 We have known for some time that there
appears to be a link between urate level, heart disease,
and mortality.8 We also know that higher urate levels
are often found in disease states such as chronic kidney
disease and diabetes, which are themselves associated
with an increased cardiovascular risk.22 However, re-
duction in urate alone is not enough to reduce car-
diovascular risk in at-risk populations.23 In addition,
the association between urate level and mortality is
slightly more complex in the HD population than in
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Table 3. Summary of Exposure to Allopurinol and Safety Blood Tests at Each Study Visit
Variable
Laboratory
Reference
Range Baseline Visit 3 Visit 4 Visit 5 Visit 6 Visit 7
Expected cumulative
allopurinol exposure
per patient (mg)
Not applicable 0 300 900 1650 2550 3600
Expected number of
doses of allopurinol
per patient
Not applicable 0 3 6 9 12 15
White cell count
(cells/mm3)
4000–11 000 7630 ± 2894 7350 ± 2690 7750 ± 2577 7840 ± 2768 8250(IQR 7050–8900) 7820 ± 3111
Hemoglobin (g/dL) 13–18 12.0 ± 1.2 11.2 ± 0.9 11.4 ± 1.0 11.1 ± 0.9 11.1 ± 0.6 10.9 ± 0.5
Albumin (g/dL) 3.5–5.0 3.3 ± 0.4 3.4 ± 0.4 3.4 ± 0.4 3.3 ± 0.4 3.3 ± 0.5 3.3 ± 0.5
Bilirubin (mg/dL) 0–1.2 0.3 (IQR 0.2–0.4) 0.3 (IQR 0.2–0.4) 0.2 (IQR 0.2–0.3) 0.3 ± 0.2 0.3 ± 0.1 0.3 ± 0.2
Alkaline phosphatase
(U/L)
30–130 117 ± 64 107 ± 50 102 ± 42 99 ± 39 104 ± 45 86 (IQR 74–93)
Alanine
aminotransferase
(U/mL)
5–55 18.2 ± 5.7 17.8 ± 6.1 16.9 ± 5.2 17.8 ± 6.1 18.1 ± 6.1 17.9 ± 7.7
Phosphate (mg/dL) 2.5–4.6 5.6 ± 0.6 5.9 ± 1.2 5.6 ± 0.9 5.6 ± 0.9 5.6 ± 1.2 5.6 ± 0.9
Potassium (mmol/L) 3.5–5.3 5.3 ± 0.6 5.2 ± 0.5 5.2 ± 0.7 5.2 ± 0.5 5.4 ± 0.6 5.3 ± 0.5
Data is presented as mean ± standard deviation or median (IQR 1–3). IQR, interquartile range.
other populations. The majority of studies suggest a
J-shaped mortality relationship with urate exists, with
both low and high levels of urate associated with an
increased mortality risk.24–27 This is likely to reflect
that the lowest urate levels are found in frailer and less
well-nourished HD patients. This J-shaped relationship
does not detract from the fact that for most HD
patients, reducing urate levels is a potential therapeu-
tic target to try to reduce an elevated cardiovascular
risk.
Allopurinol has been shown to regress left ventric-
ular mass in ischemic heart disease, in type 2 diabetes,
and in early chronic kidney disease.10,11,14 The reasons
allopurinolmight regress left ventricularmass are sever-
alfold. First, allopurinol profoundly reduces oxidative
stress. Oxidative stress is a well-known important driver
of left ventricular hypertrophy.28 Allopurinol has also
been shown to significantly improve arterial endothelial
function11,29 and can lead to improved arterial com-
pliance and reduced ventricular afterload.14,30 Reduced
ventricular afterload because of better arterial com-
pliance can regress left ventricular hypertrophy.11,14 As
left ventricular hypertrophy is associated with increased
mortality,31 regression of left ventricular mass by al-
lopurinol may be associated with the same increased
survival as seen in other clinical trials in which regres-
sion of left ventricular mass has been achieved.32 How-
ever, a large clinical trial of allopurinol versus placebo
focusing on major adverse cardiovascular events in a
vulnerable group would be required to show the ability
of allopurinol to achieve this.
In the general population, a treat-to-target approach
can be used to determine urate dosing with doses of up
to 900 mg per day being licensed to achieve a significant
reduction in urate levels.3 For patients with end-stage
renal disease requiring HD, there are no data to guide
management. The maximum recommended dose in the
United Kingdom is 300 mg after HD (ie, every second
day).2 However, until now, little was known about the
overall effect such a dose had on circulating urate levels.
Our dose-finding study has shown that allopurinol at
doses up to 350 mg does not achieve large reductions in
urate. This is likely to be due to dialysis-related factors.
First, urate is a small compound and is therefore,
like urea, largely removed by dialysis at each HD
session. This means that after each dialysis session,
patients will start with a low circulating serum urate.
In the interdialytic gap, urate will reaccumulate, as
it will not be excreted as normal via the renal tract.
This intermittent removal of urate is likely to explain
why this group of patients largely had a predialysis
urate within the normal range, whereas patients in a
chronic kidney disease allopurinol study (who were not
receiving dialysis) had slightly more elevated baseline
urates.11 The urate levels seen in that previous chronic
kidney disease study are in keeping with patients with
chronic kidney disease (CKD) being commonly found
to have higher levels of circulating urate.5
Another dialysis-specific factor in this study is that
allopurinol itself is also removed by dialysis. This
means that if a single allopurinol tablet was missed at
the preceding dialysis session to the study visit dialysis
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session, then there would be effectively no allopurinol
in the patient’s system. Although compliance was very
good in this study, on 2 confirmed occasions when an
allopurinol tablet was missed, urate was not reduced at
the next session.
Why Aim for a Fixed Urate Reduction?
We chose a target reduction in urate of 41%, as we
considered this a reasonable and safe target for urate
lowering for both clinical and research purposes. In
previous work, in the CKD population, a urate reduc-
tion of 41% was associated with a significant regres-
sion in left ventricular mass.11 The regression in left
ventricular mass was independent of urate reduction,
which supportes the theory that the novel actions of
allopurinol other than urate lowering are important.
This means it is possible to have some confidence that
the potential benefits of allopurinol might still be seen
in the dialysis population, even though their urate levels
were not dramatically reduced.
It is worth noting that allopurinol is generally used
with caution in the CKD population because of con-
cerns over an increased incidence of skin reactions
including the very rare but serious allopurinol hyper-
sensitivity syndrome.33 Accordingly, dose reduction is
recommended and normal in the renal population.2 In
keepingwith published recommendations to ensure safe
prescribing of allopurinol in end-stage renal disease,19
the dose escalation was therefore planned to stop in
each patient when serum urate had fallen by 50% from
the screening visit urate in that patient. In this study, we
saw no serious adverse events, and the only 3 adverse
events that could have possibly been related to allop-
urinol were separate self-limiting episodes of nausea
and diarrhea. Reassuringly there were also no adverse
changes in safety blood tests that could be attributed to
allopurinol. Therefore, although it was very small, this
study lends some support for allopurinol at doses up to
300 and 350 mg being well tolerated in this population.
This study has several limitations. First, this was a
very small single-center study with a relatively short du-
ration of investigation. The population was not racially
diverse and was 90% male. Given the small numbers
in this study, urate levels could have also been affected
by other factors outside the control of the study team
(for example, a shortened dialysis session because of
vascular access issues). Nevertheless, similarly sized
studies have been used by the Food and Drug Admin-
istration for the licensing of other drugs in end-stage
renal disease, including rivaroxiban and dabigatran.34,35
The urate reduction by allopurinol demonstrated in this
study was less than originally anticipated. However, de-
spite this, the investigators believe that this dose-finding
studywas sufficient to allow an informed decision about
which dose of allopurinol to safely use for the main
ALTERED trial. The results of the main trial may
provide further clinically relevant information that will
assist nephrologists when prescribing allopurinol for
clinical purposes.
Conclusion
We sought to determine which dose of allopurinol,
up to 350 mg, would significantly reduce urate in a
group of 10 dialysis patients. No dose of allopurinol
reduced urate by 50%, and this is likely to be be-
cause of dialysis-related factors. However, in this small
study, all doses of allopurinol were well tolerated, and
300 mg was associated with the most significant drop in
urate levels. The dose of 300 mg was chosen as the dose
of allopurinol to be used in the double-blind, placebo-
controlled ALTERED study, which seeks to answer
the question, does allopurinol regress left ventricular
mass in end-stage renal disease? This study suggests that
300 mg may be a reasonable dose of allopurinol to use
in dialysis patients if a significant reduction in urate is
sought for clinical purposes. Lower doses of allopurinol
are unlikely to have a significant effect on urate levels.
The larger double-blind study of allopurinol 300 mg
against placebo will add further useful information
about the safety and tolerability of such a dose in
dialysis populations.
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